Trial/Author (Year) | Subpopulation or Population | Treatment | No. of Patients | OS | PFS | ||
---|---|---|---|---|---|---|---|
Median (95% CI), Months | HR (95% CI) | Median (95% CI), Months | HR(95% CI) | ||||
Johnson et al. (2016) [33] | High (>  23.1 mutations per mb) | NIVO, PEM, and ATEZO | 65 | NE | NR | NE | NR |
Intermediate (3.3–23.1 mutations per mb) | 65 | 9.9 (NR) | NR | 2.9 (NR) | NR | ||
Low (<  3.3 mutations per mb) | 65 | 12.3 (NR) | NR | 2.8 (NR) | NR | ||
Roszik et al. (2016) [34] | Predicted TML ≤ 100 | IPI | 19 | 19.14 (NR) | 0.35 (0.16–0.77) | NR | NR |
Predicted TML > 100 | 57 | Undefined (NR) | NR | NR | |||
Yaghmour et al. (2016) [28] | TML: top quintile | NIVO, PEM, and IPI | 50 (overall patients) | NR | 3.29(0.75–25.53) | NR | NR |
TML: other quintiles combined | NR | NR | NR |